Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study.
ABO mismatch
HSC transplantation
pure red cell aplasia
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
11
11
2020
accepted:
12
03
2021
pubmed:
13
4
2021
medline:
29
9
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
Pure red cell aplasia (PRCA) following allogeneic haematopoietic stem cell transplantation (aHSCT) with major ABO incompatibility is responsible for transfusion dependent anaemia, impaired quality of life and iron overload. We conducted a retrospective study, over a 10-year period, which included all consecutive patients who received a major ABO mismatched aHSCT, to assess the impact of specific treatment on PRCA. We did not observe any PRCA in the 57 aHSCT issued from cord blood. Among the remaining 631 patients, cumulative incidence of PRCA was 10·5% [range 8·2-13.0]. The median duration of resolved PRCA was 171 days [IQR 116; 261]. Pre-transplant high isohaemagglutinins titre was associated with an increased risk of PRCA (P < 10
Substances chimiques
ABO Blood-Group System
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
814-826Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood. 2000;96(3):1150-6.
Stussi G, Muntwyler J, Passweg JR, Seebach L, Schanz U, Gmür J, et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30(2):87-93.
Seebach JD, Stussi G, Passweg JR, Loberiza FR, Gajewski JL, Keating A, et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol. Blood Marrow Transplant. 2005;11(12):1006-13.
Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S, et al. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica. 2008;93(11):1686-93.
Blin N, Traineau R, Houssin S, Peffault de Latour R, Petropoulou A, Robin M, et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant. 2010;16(9):1315-23.
Wiesneth M, Hertenstein B, Bunjes D, Schmeiser T, Maccari B, Northoff H, et al. ABO-incompatible bone marrow transplantation. Beitr Infusionsther. 1992;30:354-8.
Wang Z, Sorror ML, Leisenring W, Schoch G, Maloney D, Sandmaier BM, et al. The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative hematopoietic cell transplantation (HCT). Biol. Blood Marrow Transplant. 2010;16(2):S261-S262.
Gmur JP, Burger J, Schaffner A, Neftel K, Oelz O, Frey D, et al. Pure red cell aplasia of long duration complicating major ABO- incompatible bone marrow transplantation [see comments]. Blood. 1990;75(1):290-5.
Stussi G, Halter J, Bucheli E, Valli PV, Seebach L, Gmür J, et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica. 2009;94(2):239-48.
Curley C, Pillai E, Mudie K, Western R, Hutchins C, Durrant S, et al. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange: SECRETOR PLASMA IN ABO-MISMATCHED HPCT. Transfusion. 2012;52(2):291-7.
Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013;160(6):798-805.
Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, et al. Pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplantation is associated with severe pancytopenia. Biol Blood Marrow Transplant. 2016;22(5):961-5.
Shimizu R, Takeuchi M, Sakaida E, Ohwada C, Toyosaki M, Machida S, et al. Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation. Ann Hematol. 2019;98(7):1781-3.
Blacklock HA, Katz F, Michalevicz R, Hazlehurst GRP, Davies L, Prentice HG, et al. A and B blood group antigen expression on mixed colony cells and erythroid precursors: relevance for human allogeneic bone marrow transplantation. Br J Haematol. 1984;58(2):267-76.
Sahovic EA, Flick J, Graham CD, Stuart RK. Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci. 1991;302(6):369-73.
Selleri C, Raiola A, Rosa GD, Luciano L, Pezzullo L, Picardi M, et al. CD34+ -enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant. 1998;22(6):605-7.
Veelken H, Wäsch R, Behringer D, Bertz H, Finke J. Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning. Bone Marrow Transplant. 2000;26(8):911-5.
Ebihara Y, Manabe A, Tsuruta T, Ishikawa K, Hasegawa D, Ohtsuka Y, et al. The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplastic syndrome developing from kostmann syndrome. Int J Hematol. 2007;86(5):446-50.
Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98(6):1687-94.
Zhu K, Li J, Zhang T, Zhong J, Chen J. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematology. 2007;12(2):117-21.
Lee J-H, Lee K-H, Kim S, Lee J-S, Kim S-H, Kwon S-W, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25(2):179-84.
Wada S, Asano-Mori Y, Yamamoto H, Yuasa M, Kageyama K, Kaji D, et al. No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation. Bone Marrow Transplant. 2019;54(5):765-8.
Damodar S, George B, Mammen J, Mathews V, Srivastava A, Chandy M. Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants. Bone Marrow Transplant. 2005;36(3):233-5.
Kanda Y, Tanosaki R, Nakai K, Saito T, Ohnishi M, Niiya H, et al. Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor. Br J Haematol. 2002;118(1):128-31.
Heyll A, Aul C, Runde V, Arning M, Schneider W, Wernet P. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation with recombinant erythropoietin [letter; comment]. Blood. 1991;77(4):906.
Paltiel O, Cournoyer D, Rybka W. Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion. 1993;33(5):418-21.
Fujisawa S, Maruta A, Sakai R, Taguchi J, Tomita N, Ogawa K, et al. Pure red cell aplasia after major ABO-incompatible bone marrow transplantation: two case reports of treatment with recombinant human erythropoietin. Transpl Int. 1996;9(5):506-8.
Busca A, Dellacasa C, Giaccone L, Manetta S, Biale L, Godio L, et al. Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(8):1765-70.
Or R, Naparstek E, Mani N, Slavin S. Treatment of pure red-cell aplasia following major ABO-mismatched T-cell-depleted bone marrow transplantation. Transplant Int. 1991;4(2):99-102.
Ohta S, Yokoyama H, Ise T, Takasawa K, Wada T, Nakao S, et al. Apheresis therapy for prolonged red cell aplasia after major ABO-mismatched bone marrow transplantation. Intern Med. 1997;36(7):487-91.
Worel N, Greinix HT, Schneider B, Kurz M, Rabitsch W, Knöbl P, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion. 2000;40(5):543-50.
Rabitsch W, Knöbl P, Greinix H, Prinz E, Kalhs P, Hörl WH, et al. Removal of persisting isohaemagglutinins with Ig-Therasorb® immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2003;18(11):2405-8.
Rabitsch W, Knöbl P, Prinz E, Keil F, Greinix H, Kalhs P, et al. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb ® immunoadsorption. Bone Marrow Transplant. 2003;32(10):1015-9.
Tsai H-J, Lin S-F, Liu T-C, Chang C-S, Hsiao H-H, Chen T-P. Pure red cell aplasia after ABO major-mismatched allogeneic peripheral blood stem cell transplantation successfully treated with plasma exchange and low-dose steroid: two case reports. Kaohsiung J Med Sci. 2004;20(3):128-32.
Dellacasa CM, D’Ardia S, Allione B, Aydin S, Tassi V, Francisci T, et al. Efficacy of plasmapheresis for the treatment of pure red blood cell aplasia after allogeneic stem cell transplantation. Transfusion. 2015;55(12):2979-82.
Sackett K, Cohn CS, Fahey-Ahrndt K, Smith AR, Johnson AD. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apheresis. 2018;33(1):108-12.
Bar B, Dijk V, Schattenberg A, de Man A, Kunst V, de Witte T. Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte-depleted bone marrow. Bone Marrow Transplant. 1995;16(6):793-9.
Yang M-H, Hsu H-C. Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review. Ann Hematol. 2001;80(5):299-301.
Sharma SK, Kumar S, Agrawal N, Mishra P, Seth T, Mahapatra M. Oral high dose dexamethasone for pure red cell aplasia following ABO-mismatched allogeneic peripheral blood stem cell transplantation: a case report. Indian J Hematol Blood Transfus. 2015;31(2):317-8.
Fang B, Song Y, Zhao RC, Han Q, Cao Y. Treatment of resistant pure red cell aplasia after major abo-incompatible bone marrow transplantation with human adipose tissue-derived mesenchymal stem cells. Am J Hematol. 2007;82(8):772-3.
Fang B, Song Y, Li N, Li J, Han Q, Zhao RC. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Ann Hematol. 2009;88(3):261-6.
Sergeevicheva V, Kruchkova I, Chernykh E, Shevela E, Kulagin A, Gilevich A, et al. Rapid recovery from chronic PRCA by MSC infusion in patient after major ABO-mismatched alloSCT. Case Rep Med. 2012;2012:1-4.
Maschan A, Skorobogatova E, Balashov D, Pashanov E, Trakhtman P, Schipitzina I, et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant. 2002;30(6):405-7.
Zhu K, Chen J, Chen S. Treatment of Epstein-Barr Virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review. Hematology. 2005;10(5):365-70.
Sorà F, Matteis SD, Piccirillo N, Chiusolo P, Laurenti L, Putzulu R, et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion. 2005;45(4):643-5.
Mota KO, Macedo MC, Silva R. Successful treatment of pure red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with repeated doses of the single-agent rituximab: a case report. Blood. 2007;110(11):4934.
Zhidong W, Hongmin Y, Hengxiang W. Successful treatment of pure red cell aplasia with a single low dose of rituximab in two patients after major ABO incompatible peripheral blood allogeneic stem cell transplantation. Transfus Med. 2012;22(4):302-4.
Bavaro P, Girolamo GD, Olioso P, Papalinetti G, Iacone A, Accorsi P, et al. Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation. Br J Haematol. 1999;104(4):930-1.
Verholen F, Stalder M, Helg C, Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol. 2004;73(6):441-6.
Poon L-M, Koh LP. Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib. Bone Marrow Transplant. 2012;47(6):870-1.
Khan F, Linden MA, Zantek ND, Vercellotti GM. Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation. Transfus Med. 2014;24(3):187-8.
Shahan J, Hildebrandt G. Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma. Transfus Med. 2015;25(5):342-4.
Yamaguchi M, Sakai K, Murata R, Ueda M. Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30(8):539-41.
Hirokawa M, Fukuda T, Ohashi K, Hidaka M, Ichinohe T, Iwato K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 2013;19(7):1026-32.
Means RT. Pure red cell aplasia. Blood. 2016;128(21):2504-9.
Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kobayashi T, et al. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan. Bone Marrow Transplant. 2007;40(6):523-8.
Zaucha JM, Mielcarek M, Takatu A, Little M-T, Gooley T, Baker J, et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. Br J Haematol. 2002;119(3):740-50.
Santamaría A, Sureda A, Martino R, Domingo-Albós A, Muñiz-Díaz E, Brunet S. Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant. 1997;20(12):1105-7.
Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, et al. Rational management approach to pure red cell aplasia. Haematologica. 2018;103(2):221-30.
Petropoulou AD, Porcher R, de Latour RP, Xhaard A, Weisdorf D, Ribaud P, et al. Increased infection rate after preemptive rituximab treatment for Epstein-Barr Virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2012;94(8):879-83.
Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 2018;379(19):1846-50.
Rautenberg C, Kaivers J, Germing U, Haas R, Ackerstaff S, Hoffmann T, et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2020;55(6):1191-3.
Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol. 2019;94(8). https://doi.org/10.1002/ajh.25515.
Salas MQ, Alahmari A, Lipton JH. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol. 2020;104(2):145-7.
Tolbert VP, Goldsby R, Huang J, Shimano K, Melton A, Willert J, et al. Daratumumab is effective in the treatment of refractory post-transplant autoimmune hemolytic anemia: a pediatric case report. Blood. 2016;128(22):4819.
Migdady Y, Gupta R, Ediriwickrema A, Socola F, Arai S, Martin BA. A case report of refractory immune thrombocytopenia (ITP) following reduced intensity conditioning (RIC) hematopoietic cell transplantation (HCT) for Myelodysplastic Syndrome (MDS) successfully treated with off-label use of daratumumab. Blood. 2018;132(Suppl 1):4976.
Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018;2(19):2550-3.
Blennerhassett R, Sudini L, Gottlieb D, Bhattacharyya A. Post-allogeneic transplant Evans syndrome successfully treated with daratumumab. Br J Haematol. 2019;187(2):e48-e51.
Griffith LM, McCoy JP, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128(5):668-75.
Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol. 2006;34(5):688-94.